NCT04899908: Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

NCT04899908
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must meet at least one of the following: 1 HER2+ breast cancer, 2 Metastases that are greater than or equal to 2cm, 3 Locally recurrent metastases after prior stereotactic radiation or whole brain radiation
Exclusions: Patients with widespread, definitive leptomeningeal disease; Patients requiring radiation to greater than 10 targets (if naïve to whole brain radiation) or greater than 20 targets (if whole brain radiation has been given previously)
https://ClinicalTrials.gov/show/NCT04899908

Comments are closed.

Up ↑